| Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. | |
| | |
MedLine Citation:
|
PMID: 21712485 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Tyrosine 1248 is one of the autophosphorylation sites of human epidermal growth factor receptor (HER)-2. We determined the prognostic value of the expression level of tyrosine 1248-phosphorylated HER-2 (pHER-2) in patients with HER-2(+) primary breast cancer using a reverse-phase protein array. PATIENTS AND METHODS: The optimal cutoff value of pHER-2 for segregating disease-free survival (DFS) was determined by receiver operating characteristic (ROC) curve analysis. Five-year DFS for pHER-2 expression level was estimated with the Kaplan-Meier method using both derivation (n = 162) and validation (n = 227) cohorts. RESULTS: Of the 162 patients in the derivation cohort, 26 had high HER-2 expression levels. The area under the ROC curve for pHER-2 level and DFS was 0.662. Nineteen of the 162 patients (11.7%) had high pHER-2 expression levels (pHER-2(high)); 143 patients (88.3%) had low pHER-2 expression levels (pHER-2(low)). Among the 26 patients with high HER-2 expression levels, the 17 pHER-2(high) patients had a significantly lower 5-year DFS rate than the nine pHER-2(low) patients (23.5% versus 77.8%). On multivariate analysis, only pHER-2(high) independently predicted DFS in the Cox proportional hazards model. In the validation cohort, among 61 patients with high HER-2 expression, the difference in 5-year DFS rates between pHER-2(high) (n = 7) and pHER-2(low) (n = 54) patients was marginal (57.1% versus 81.5%). CONCLUSION: In patients with HER-2(+) primary breast cancer, pHER-2(high) patients had a lower 5-year DFS rate than pHER-2(low) patients. Quantification of pHER-2 expression level may provide prognostic information beyond the current standard HER-2 status. |
| | |
Authors:
|
Naoki Hayashi; Takayuki Iwamoto; Ana M Gonzalez-Angulo; Jaime Ferrer-Lozano; Ana Lluch; Naoki Niikura; Chandra Bartholomeusz; Seigo Nakamura; Gabriel N Hortobagyi; Naoto T Ueno |
Related Documents
:
|
3456785 - Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations... 8689105 - The value of exfoliative urine cytology in combination with flexible cystoscopy in the ... 8378065 - Assessment of cervical metastatic disease. 1565385 - Endometrial adenocarcinoma without prior hormone replacement in a diabetic patient with... 10856185 - Mercury intolerance in relation to superoxide dismutase, glutathione peroxidase, catala... 17907435 - Neuromuscular disease as the cause of late clubfoot relapses: report of 4 cases. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2011-06-28 |
Journal Detail:
|
Title: The oncologist Volume: 16 ISSN: 1549-490X ISO Abbreviation: Oncologist Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-08-01 Completed Date: 2012-01-31 Revised Date: 2012-04-18 |
Medline Journal Info:
|
Nlm Unique ID: 9607837 Medline TA: Oncologist Country: United States |
Other Details:
|
Languages: eng Pagination: 956-65 Citation Subset: IM |
Affiliation:
|
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Breast Neoplasms / enzymology*, genetics, pathology Disease-Free Survival Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Middle Aged Phosphorylation Prognosis Receptor, erbB-2 / biosynthesis, genetics, metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
1K23CA121994-01/CA/NCI NIH HHS; 1R21CA120248-01/CA/NCI NIH HHS; CA016672/CA/NCI NIH HHS; K23 CA121994-01/CA/NCI NIH HHS; P30 CA016672-36/CA/NCI NIH HHS; R01 CA123318-01/CA/NCI NIH HHS; R01 CA123318-01A1/CA/NCI NIH HHS; R01 CA123318-02/CA/NCI NIH HHS; R01 CA123318-03/CA/NCI NIH HHS; R01 CA123318-04/CA/NCI NIH HHS; R01 CA123318-05/CA/NCI NIH HHS; R01 CA123318-06/CA/NCI NIH HHS; R21 CA120248-01/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quality of life and clinical outcome comparison of semitendinosus and gracilis tendon versus patella...
Next Document: A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced he...